- Published on
Clinical Toxicology — Quinine
1. Overview
Quinine is a naturally occurring cinchona alkaloid with antimalarial activity and important cardiovascular, neurologic, ocular, metabolic, and hematologic effects.
It is obtained from the bark of Cinchona species and is also present in small quantities in tonic water.
Quinine poisoning is particularly concerning because it can cause two distinct forms of severe toxicity:
- Dose-dependent poisoning: Cinchonism, visual or hearing impairment, seizures, hypoglycemia, cardiac conduction abnormalities, ventricular dysrhythmias, and cardiovascular collapse.
- Idiosyncratic immune-mediated reactions: Severe thrombocytopenia, hemolysis, and thrombotic microangiopathy, sometimes occurring after exposure to an ordinary therapeutic dose or quinine-containing beverage.
Acute ingestion of several grams can be fatal. Visual loss may be permanent despite recovery from the systemic poisoning.
There is no specific antidote. Treatment prioritizes airway and circulatory support, correction of glucose and electrolyte abnormalities, management of dysrhythmias, and early ophthalmologic evaluation when vision is affected.
The primary clinical lesson is that quinine’s serious adverse effects are not limited to large overdoses.
2. Forms and contemporary uses
Pharmaceutical quinine
The principal U.S. prescription product is quinine sulfate, marketed as Qualaquin, supplied in 324 mg capsules.
Its FDA-approved indication is treatment of uncomplicated Plasmodium falciparum malaria.
It is not approved for malaria prevention, severe malaria, or nighttime leg cramps.
Modern malaria treatment
Artemether–lumefantrine is generally preferred for uncomplicated malaria when appropriate for the infecting species and location of acquisition.
Quinine sulfate, combined with an appropriate second antimalarial such as doxycycline or clindamycin, remains an alternative in selected circumstances.
For severe malaria, intravenous artesunate is the preferred treatment in the United States.
Quinine should not be used as a substitute for appropriate severe-malaria treatment merely because it is available.
Nighttime leg cramps
Quinine was historically prescribed for nocturnal leg cramps, including doses around 260–325 mg at bedtime.
This practice is no longer recommended.
The FDA boxed warning states that the potential for fatal hematologic reactions outweighs any possible benefit for this generally benign condition.
Tonic water
Quinine is used as a bitter flavoring agent in tonic water.
U.S. regulations permit up to 83 mg/L, equivalent to 83 parts per million, in carbonated beverages.
The small quinine content of ordinary tonic water generally does not produce dose-dependent quinine poisoning.
However, individuals with quinine-dependent antibodies can experience severe immune reactions after much smaller exposures.
Other sources
Additional sources include cinchona bark, herbal products, imported medicines, and quinine used as an adulterant of illicit drugs.
Quinine and quinidine are chemically related but are not interchangeable medications. Both can impair cardiac conduction and prolong repolarization.
3. Toxicokinetics and toxic dose
Quinine is generally absorbed rapidly after oral ingestion.
It is extensively metabolized in the liver, principally through CYP3A4, and is substantially bound to plasma proteins.
Its elimination half-life after therapeutic dosing is commonly approximately 10–12 hours, although it may be prolonged in overdose, severe malaria, older age, and organ dysfunction.
Toxic dose
A precise lethal dose cannot be established.
Serious toxicity has occurred after ingestion of several grams, and fatalities have been reported after approximately 2–8 g in adults.
Historical thresholds such as 5–10 g should not be interpreted as reliable safety boundaries.
Individual susceptibility, coingestants, underlying cardiac disease, and timing of treatment substantially affect clinical outcomes.
Serum concentrations
Specialized laboratories can measure quinine concentrations.
Historical studies associated concentrations around 10–15 mg/L with visual symptoms and higher concentrations with increasing cardiac risk.
However, concentration–toxicity relationships are imperfect and are influenced by protein binding and clinical circumstances.
Treatment must not be delayed while awaiting a quinine concentration.
When rapidly available, serial concentrations may assist specialist assessment of a severe overdose, but they do not replace clinical examination and ECG monitoring.
4. Pathophysiology
Cinchonism
Cinchonism is a characteristic syndrome caused by quinine and related cinchona alkaloids.
It may develop during therapeutic treatment or overdose.
Manifestations include tinnitus, headache, nausea, dizziness, hearing disturbance, and visual symptoms.
Severe poisoning can cause profound sensory impairment, seizures, coma, and cardiovascular complications.
Cardiac toxicity
Quinine has class I antiarrhythmic-like properties and affects cardiac ion channels.
It slows conduction, which can produce PR prolongation and QRS widening.
It also prolongs repolarization, increasing the QT interval and the risk of torsades de pointes.
Alpha-adrenergic blocking and myocardial depressant effects may contribute to hypotension.
Ocular toxicity
Quinine can cause direct retinal toxicity, including injury involving photoreceptors and retinal function.
Severe overdose may produce sudden, profound visual loss.
Retinal vascular changes may occur, but vascular spasm alone does not adequately explain the injury.
Hypoglycemia
Quinine stimulates pancreatic insulin secretion.
The resulting hyperinsulinemia can cause clinically significant hypoglycemia, particularly during pregnancy and treatment of malaria.
Immune-mediated toxicity
Some individuals develop drug-dependent antibodies that react with platelets or other blood cells in the presence of quinine.
This can produce thrombocytopenia, hemolysis, and thrombotic microangiopathy.
Unlike ordinary overdose toxicity, these reactions are not reliably dose-dependent and can become more severe following re-exposure.
5. Clinical manifestations
Mild cinchonism
The initial presentation may involve headache, tinnitus, dizziness, nausea, vomiting, flushing, and sweating.
Hearing impairment and visual disturbance suggest more significant toxicity.
Ocular toxicity
Patients may report blurred vision, abnormal color perception, reduced visual acuity, or constriction of the visual field.
Severe poisoning may produce sudden bilateral blindness.
Visual acuity can improve during recovery while significant peripheral visual-field loss persists.
Permanent impairment remains possible.
Auditory toxicity
Tinnitus is common.
Temporary hearing impairment may occur during therapeutic use or poisoning.
Severe overdose can cause substantial hearing loss, which may occasionally persist.
Cardiovascular toxicity
Important manifestations include:
- Sinus tachycardia or bradycardia.
- Hypotension.
- PR prolongation.
- QRS widening.
- QT prolongation.
- Atrioventricular block.
- Ventricular tachycardia.
- Torsades de pointes.
- Ventricular fibrillation.
- Cardiogenic shock or cardiac arrest.
Neurologic toxicity
Severe poisoning can cause confusion, ataxia, drowsiness, seizures, coma, and respiratory depression.
Gastrointestinal symptoms
Nausea, vomiting, abdominal pain, and diarrhea are common.
Metabolic abnormalities
Hypoglycemia may cause sweating, confusion, seizures, or impaired consciousness.
Electrolyte abnormalities may aggravate cardiac toxicity.
Hematologic and renal complications
Immune-mediated reactions may produce petechiae, bruising, bleeding, hemolytic anemia, acute kidney injury, and thrombotic microangiopathy.
These complications can occur without a massive ingestion.
6. Quinine-induced thrombocytopenia and thrombotic microangiopathy
This is among the most important modern additions to the older chapter.
Immune thrombocytopenia
Quinine-dependent antibodies can cause abrupt and profound platelet destruction.
Patients may develop:
- Petechiae.
- Purpura.
- Nosebleeds or gum bleeding.
- Hematuria.
- Gastrointestinal bleeding.
- Severe thrombocytopenia.
The reaction may appear after prior sensitization, and re-exposure can produce a rapid recurrence.
Thrombotic microangiopathy
Quinine-induced thrombotic microangiopathy (TMA) can cause:
- Microangiopathic hemolytic anemia.
- Thrombocytopenia.
- Acute kidney injury.
- Other organ dysfunction.
It may resemble thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome.
Diagnosis
Investigations may include CBC, peripheral blood smear, creatinine, bilirubin, lactate dehydrogenase, haptoglobin, and urinalysis.
ADAMTS13 testing may be necessary when TTP is a consideration.
Drug-dependent antibody testing may confirm quinine-associated immune injury, but results are not usually available for immediate management.
Treatment
Stop quinine immediately and avoid all future exposure.
Provide appropriate supportive care, including management of bleeding, anemia, and kidney dysfunction.
Hematology and nephrology consultation may be necessary.
Plasma exchange is lifesaving for certain forms of TTP but has no established routine benefit in quinine-induced TMA.
When TTP cannot initially be excluded, urgent management may include plasma exchange while definitive diagnostic assessment proceeds.
Prevention
Patients with confirmed quinine-induced immune thrombocytopenia or TMA must avoid quinine-containing medications, tonic water, and other sources of quinine.
The reaction may recur even after a small exposure.
7. Diagnostic evaluation
Exposure history
Establish the exact preparation, dose, timing, and possible coingestants.
Ask about quinine-containing medications, tonic water, cinchona products, and imported remedies.
Determine whether previous quinine exposure caused unexplained bruising, bleeding, kidney injury, or severe illness.
Immediate investigations
In clinically important overdose, obtain:
- 12-lead ECG and continuous cardiac monitoring.
- Bedside blood glucose.
- Electrolytes, including potassium and magnesium.
- Creatinine and kidney function.
- Blood gas and lactate when severe poisoning is suspected.
- Complete blood count.
Additional tests depend on symptoms and suspected complications.
Coingestants
Consider acetaminophen and salicylate testing after deliberate or uncertain overdose.
Ophthalmologic examination
Patients with visual symptoms require urgent ophthalmologic assessment.
Evaluation may include visual acuity, pupils, fundus examination, visual fields, and selected retinal imaging or electrophysiologic studies.
Hematologic investigations
Patients with thrombocytopenia, bleeding, anemia, or kidney dysfunction require assessment for immune-mediated toxicity and TMA.
Quinine concentrations
Routine quinine concentration measurement is unnecessary in mild cases.
Specialized testing can help assess selected severe poisonings but should not determine whether immediate supportive treatment begins.
8. Emergency treatment
Initial priorities
Severe quinine poisoning requires prompt emergency care.
The principal priorities are:
- Stabilize airway, breathing, and circulation.
- Obtain and repeat ECGs.
- Monitor and correct glucose.
- Treat seizures and dysrhythmias.
- Assess visual function.
- Identify immune-mediated hematologic injury.
- Consult a poison control center or medical toxicologist.
Airway and breathing
Provide oxygen for hypoxemia.
Patients with seizures, coma, or respiratory failure may require assisted ventilation and intubation.
Hypoglycemia
Check glucose promptly and repeatedly in significant poisoning.
Treat hypoglycemia with intravenous dextrose according to standard emergency protocols.
A continuous glucose infusion may be necessary when hypoglycemia recurs.
Seizures
Benzodiazepines are first-line treatment.
Persistent seizures require escalation according to standard status epilepticus management.
Correct accompanying hypoglycemia, hypoxemia, and important electrolyte disturbances.
Hypotension
Provide appropriately titrated isotonic crystalloid when indicated.
Persistent shock may require norepinephrine and intensive-care management.
Avoid routine excessive fluid administration in patients with myocardial dysfunction or pulmonary edema.
9. Management of cardiac toxicity
Continuous ECG monitoring
Patients with significant overdose, syncope, hypotension, abnormal ECG findings, or serious symptoms require continuous monitoring.
QRS widening
Marked QRS widening suggests clinically important cardiac conduction toxicity.
Intravenous sodium bicarbonate may be considered for severe QRS widening or suspected sodium-channel-blocking dysrhythmias, with treatment directed by ECG and acid-base response.
Evidence specifically supporting sodium bicarbonate in quinine poisoning is limited, so specialist toxicology advice is important.
QT prolongation
Correct potassium and magnesium abnormalities.
Avoid additional QT-prolonging medications.
Torsades de pointes
Treat according to current resuscitation guidance.
Intravenous magnesium sulfate is indicated for torsades de pointes.
Hemodynamically unstable sustained ventricular dysrhythmias require appropriate electrical treatment.
Recurrent pause-dependent torsades may require temporary overdrive pacing or another specialist-directed strategy to increase heart rate.
Antiarrhythmics
Avoid reflexive use of class Ia agents such as quinidine or procainamide, which may aggravate conduction and repolarization abnormalities.
Other QT-prolonging antiarrhythmics also require caution.
Bretylium is obsolete and should be removed from the historical treatment protocol.
Bradycardia
Treat symptomatic bradycardia according to contemporary resuscitation guidance.
Atropine may be attempted when appropriate, but substantial drug-related conduction disease may not respond.
Temporary pacing is reserved for selected refractory, clinically significant bradyarrhythmias rather than being used automatically.
10. Gastrointestinal decontamination and enhanced elimination
Induced vomiting
Do not induce vomiting.
Coma, seizures, or cardiovascular collapse can develop rapidly.
Gastric lavage
Routine gastric lavage is not recommended.
Quinine is absorbed rapidly, and the benefit of lavage is uncertain.
Single-dose activated charcoal
Activated charcoal may be considered after a substantial recent ingestion when the airway is protected.
The decision should account for vomiting, altered consciousness, and anticipated benefit.
Multiple-dose activated charcoal
Quinine is one of the drugs for which multiple-dose activated charcoal can demonstrably enhance elimination.
Small pharmacokinetic studies have shown shorter plasma elimination half-lives.
However, these findings do not establish that multiple-dose charcoal prevents blindness, dysrhythmias, or death.
Its use may be considered in severe poisoning after specialist consultation when the airway is protected and gastrointestinal function is adequate.
It must not delay resuscitation.
Hemodialysis and hemoperfusion
The EXTRIP workgroup recommends against extracorporeal treatment solely to enhance quinine elimination, even in severe poisoning.
Quinine’s protein binding and distribution limit removal by these methods.
Dialysis may still be indicated for conventional reasons, such as severe kidney failure or refractory metabolic complications.
Forced diuresis
Forced acid diuresis, urinary alkalinization, and other attempts to accelerate renal elimination are not recommended.
They provide no established clinical benefit and may cause harm.
11. Management of visual and auditory toxicity
Urgent ophthalmology
Any new visual disturbance following quinine exposure warrants prompt specialist assessment.
No established ocular antidote
No intervention has reliably demonstrated reversal or prevention of quinine-induced retinal injury once severe toxicity occurs.
Stellate ganglion block
Historically, stellate ganglion block was proposed to increase retinal blood flow.
Clinical studies have not demonstrated a reliable benefit.
Stellate ganglion block and other retinal vasodilator procedures should not be used routinely.
Prognosis
Visual acuity may improve over days or weeks, but constricted visual fields or other deficits can persist.
Persistent auditory symptoms warrant audiologic assessment.
12. Pregnancy and lactation
Pregnancy
Quinine is not appropriate for attempts to induce abortion or labor.
High-dose quinine poisoning can threaten both maternal and fetal survival.
However, therapeutic quinine is not a proven abortifacient or universally contraindicated teratogen.
The historical pregnancy-category system is obsolete.
When treatment of malaria is necessary during pregnancy, current CDC guidance generally favors artemether–lumefantrine, with quinine plus clindamycin remaining an accepted alternative.
Quinine can produce maternal hyperinsulinemia and hypoglycemia, particularly during pregnancy.
Glucose monitoring is important when quinine is used.
Breastfeeding
Quinine passes into breast milk in relatively small amounts.
In most circumstances, infant exposure is well below therapeutic antimalarial doses.
However, a particularly important exception is glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Severe hemolysis has been reported in G6PD-deficient breastfed infants following maternal consumption of quinine-containing beverages.
Quinine exposure during breastfeeding requires individualized consideration, particularly when the infant has known or possible G6PD deficiency.
13. Monitoring, observation, and disposition
Significant overdose
Patients with potentially toxic ingestion require emergency assessment, serial ECGs, glucose monitoring, and observation for neurologic, ocular, and cardiovascular complications.
Observation duration
The historical six- to eight-hour discharge rule is not suitable for every exposure.
The observation period should account for dose, formulation, symptoms, ECG, glucose, coingestants, and the potential for evolving visual toxicity.
Hospital admission
Admission is appropriate for:
- Visual or auditory toxicity.
- Seizures or altered consciousness.
- Hypoglycemia.
- Significant ECG abnormalities.
- Hypotension.
- Immune-mediated thrombocytopenia.
- Hemolysis or TMA.
- Kidney injury.
- Other clinically important complications.
Intensive care
ICU admission is appropriate for coma, recurrent seizures, ventricular dysrhythmias, shock, severe hypoglycemia, or respiratory failure.
Discharge
Discharge requires stable respiratory and cardiovascular findings, reassuring serial assessments, adequate control of symptoms, and a plan for follow-up when indicated.
Visual symptoms require appropriate ophthalmologic follow-up.
Immune-mediated reactions require clear instructions for lifelong quinine avoidance.
Intentional poisoning requires appropriate mental health assessment.
14. Drug interactions and preventive precautions
Quinine is metabolized mainly through CYP3A4.
Its exposure may be altered by medications that inhibit or induce this pathway.
Important interactions include:
- QT-prolonging medications: Increased risk of ventricular dysrhythmias.
- Rifampin: May reduce quinine exposure and compromise malaria treatment.
- Certain antiretroviral medications: May substantially alter quinine pharmacokinetics.
- Digoxin: Quinine may increase exposure; monitoring may be necessary.
- Warfarin and related anticoagulants: Anticoagulant effects may be altered.
- Neuromuscular blocking agents: Quinine can potentiate neuromuscular blockade.
Patients with known QT prolongation, G6PD deficiency, myasthenia gravis, or previous serious quinine hypersensitivity may have additional contraindications.
Patient education
Quinine should not be self-prescribed for leg cramps.
Patients must understand that tonic water contains quinine and should avoid it after confirmed quinine-induced immune reactions.
Persistent tinnitus, new visual symptoms, unexplained bruising, dark urine, jaundice, or reduced urine output during quinine treatment requires urgent medical assessment.
15. Clinical pitfalls
Treating quinine as an acceptable routine therapy for nighttime leg cramps. Serious, unpredictable adverse effects outweigh its limited benefit.
Assuming severe toxicity only occurs after overdose. Immune-mediated thrombocytopenia and TMA can occur at ordinary doses.
Ignoring tonic water as a quinine source. It may trigger serious reactions in previously sensitized individuals.
Calling quinine a proven abortifacient at therapeutic doses. This is inconsistent with contemporary pregnancy evidence and malaria guidelines.
Overlooking hypoglycemia. Quinine can stimulate insulin secretion, especially during pregnancy.
Relying on a normal initial ECG. Conduction and repolarization abnormalities may evolve.
Treating QRS widening and QT prolongation as identical problems. They require different assessment and management.
Assuming normal visual acuity excludes retinal injury. Visual-field impairment may persist despite apparently recovered central vision.
Using stellate ganglion block routinely. Its benefit has not been demonstrated.
Using plasma quinine levels as a prerequisite for treatment. Emergency decisions remain primarily clinical.
Performing routine gastric lavage or induced vomiting. Both are obsolete as standard management.
Assuming charcoal-induced faster elimination guarantees improved outcomes. Pharmacokinetic benefit is not equivalent to demonstrated clinical benefit.
Using dialysis to remove quinine. EXTRIP recommends against this practice.
Missing drug-induced TMA. Thrombocytopenia, hemolysis, and kidney injury demand prompt evaluation.
Assuming all breastfed infants are unaffected. G6PD deficiency is an important exception.
Applying a universal six-hour discharge rule. Observation must reflect the severity and evolving clinical course.
Key clinical conclusions
Quinine poisoning combines potentially fatal dose-dependent cardiac and neurologic toxicity with unpredictable immune-mediated blood and kidney disorders.
The principal emergency priorities are ECG monitoring, glucose assessment, seizure and circulatory support, and urgent investigation of visual symptoms.
There is no specific antidote.
Multiple-dose activated charcoal can enhance elimination in selected severe cases, but improved patient outcomes have not been demonstrated. Dialysis and hemoperfusion are not recommended for routine drug removal.
Quinine should not be used for ordinary nighttime leg cramps. Its antimalarial role remains relevant in selected patients, including during pregnancy when clinically appropriate.